Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Healium Intelliscan is a private health technology and medical device company developing AI-enhanced point-of-care ultrasound tools for kidney disease screening and renal imaging. Its core offering is an AI-assisted handheld 3D ultrasound and software platform designed to enable earlier, non-invasive detection of chronic kidney disease and to support renal sonography outside traditional specialist imaging settings. The company emphasizes automated guidance, image-quality assessment, machine learning, and hemodynamic modeling to reduce operator skill barriers and expand access to screening. It appears to position itself at the intersection of diagnostic equipment, clinical decision support, and digital health workflow software, including the Healium Sono imaging platform. The entity requested as "Intelliscan" does not appear to be an exact standalone biotech/pharma company match; the most relevant healthcare-related match is Healium Intelliscan.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Intelliscan.